Astra Zeneca and Daiichi Sankyo’s Enhertu is the first targeted treatment prolonging progression-free survival of HER2-low breast cancer patients.

Presented in the @NEJM and at #ASCO2022 (Phase 3 Destiny-Breast04 clinical trial), Enhertu almost doubled median progression-free survival to 10.1 months over chemotherapy (5.4 months) in women with HER2-low, estrogen receptor-positive breast cancer, equivalent to a 49% reduction in the risk of progression. Around half of all breast cancers are considered HER2-low (IHC score 1), meaning that a major life-changing drug is on its way for hundreds of thousands of patients.

Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a tetrapeptide-based cleavable linker, has been approved for the treatment of patients with metastatic HER2-positive breast cancer who have received prior anti-Her2 based treatment and relapsed. It binds to and blocks the signaling of the epidermal growth factor reception 2 (Her2). 
Once it is bound to Her2, it is internalized and the payload (deruxtecan) interferes with DNA replication during mitosis, ultimately resulting in DNA damage and cell death. A main adverse event caused by Enhertu is interstitial lung disease (ILD), which will need to be carefully monitored in Her2 low breast cancer patients during the administration of this drug.

At Cerba Research, we pride ourselves on providing state-of-the art histopathology services, alongside our global central lab footprint. With a biobank of over 3,000 samples and Her2 as a validated marker, we are ready to take on the challenge to expand our capacity and support the development of more breast cancer drugs that will undoubtedly come to light on the tails of this fantastic new development.”

About Cerba Research

Cerba Research is the merge of Barc Lab, Histalim, and Cerba Xpert. All three entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Back to Blog